Trial: 202009151

A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B Cell Malignancies

Phase

I (Cancer Control)

Principal Investigator

Ghobadi, Armin

Disease Site

Non-Hodgkin’s Lymphoma

Learn more about this study at: clinicaltrials.gov